The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.
Mads Claus Rasmussen | Afp | Getty Images
Several Novo Nordisk board members will step down from their positions after clashing with the controlling shareholder on the make-up of the firm.
The Danish pharma giant, known for its weight loss and diabetes drugs, said Tuesday that board directors and the Novo Nordisk Foundation — the firm’s controlling shareholder — had failed to reach an agreement on the future composition of the board.
“The Board proposed a renewal focusing on addition of select, new competencies while also maintaining continuity, whereas the Board of the Foundation wanted a more extensive reconfiguration,” said Helge Lund, chair of the board of directors.
Copenhagen-listed shares of Novo Nordisk traded 1.2% lower as of 1:41 p.m. London time (8:41 a.m. ET).
Chair Helge Lund, Vice Chair Henrik Poulsen and the independent board members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay will not stand for election at the Extraordinary General Meeting, the company said.
Novo Nordisk said the Extraordinary General Meeting will take place on Nov. 14.
This is a breaking news story. Please refresh for updates.
